• Toppan Holdings established TOPPAN Global Medical Healthcare in Houston, Texas, to expand personalized cancer medicine support using its invivoid 3D cell culture technology.
• New unit will operate from Texas Medical Center’s Helix Park to accelerate clinical validation with UT MD Anderson Cancer Center.
• Company targets CAP/CLIA certification to support real-world deployment of patient-derived testing tools in US clinical settings.
• Houston base will also scale drug discovery support for major US pharmaceutical companies through invivoid-based screening.
• Investment includes capital of USD 2 million for the new US business.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Toppan Holdings Inc. published the original content used to generate this news brief on March 31, 2026, and is solely responsible for the information contained therein.